Drug intelligence / Profile preview

Zn0.4Fe2.6O4-NH2

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Zn0.4Fe2.6O4-NH2 is an ultrasmall zinc ferrite nanoparticle engineered as a T1 contrast agent for magnetic resonance imaging (MRI). This specific formulation features an amine modification, resulting in a positively charged surface. This positive charge is crucial for its high affinity to macrophages, which are key cellular components in atherosclerotic plaques. By selectively accumulating in macrophages within these plaques, Zn0.4Fe2.6O4-NH2 aims to enhance the visualization of atherosclerosis via MRI, offering improved diagnostic capabilities compared to conventional contrast agents like Gd-DTPA.

Beyond the preview

Go deeper on Zn0.4Fe2.6O4-NH2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zn0.4Fe2.6O4-NH2.

Explore the full profile